Drug Type Peptides |
Synonyms OLP 211, OLP211 |
Target |
Action inhibitors |
Mechanism IL-23R inhibitors(Interleukin 23 Receptor inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colitis, Ulcerative | Preclinical | China | 01 Dec 2025 | |
| Psoriasis | Preclinical | China | 01 Dec 2025 |





